UK govt sets sights on being AI drug discovery ‘world leader’

Government unveils £8M OpenBind consortium to lead in AI drug discovery | Project to build world’s largest drug–protein dataset | Backed by new Sovereign AI Unit, Consortium will be based at national synchrotron facility in Oxfordshire.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

As AI shakes up pharma and biotech, can patent law keep up?

22 May 2025 Artificial intelligence is undoubtedly impacting the biotech lifecycle, and presents myriad applications—and risks. Tim Powell, Vishnu Shankar and Ben Rowlatt of Morgan Lewis provide a detailed analysis.

Americas

ADCs, TCR, and multimodal AI: Transformative trends in 2025

23 January 2025 Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.

Americas

Big Pharma counsel embrace AI but data and legal risks loom

24 October 2024 Counsel from Pfizer, Gilead, and Bristol Myers Squibb spoke on AI’s transformative power and risks, reports Marisa Woutersen at LSPN Fall North America.

More features

IP agencies vital to pharma and biotech grind to a halt

USPTO trims workforce amid govt shutdown crisis

How impactful is the new USPTO director’s S101 decision?

Global vaccine patents rise, as data reveals shift in Big Pharma strategy

Philips wins unprecedented trade secret sanctions against Chinese defendants

Womble Bond Dickinson partners jump to rival firm

EPO ruling clarifies appeal rights, blocking third-party intervention

Biotech sues AstraZeneca and Cellectis over mRNA patents

UK govt sets sights on being AI drug discovery ‘world leader’

More on this story

Editor's picks

Editor's picks

More features